Sequential insulin therapy for HTGP offers advantages over lipid-lowering drugs in terms of earlier open diet time and reduced hospitalization costs. Nevertheless, the heightened risk of hypoglycemia necessitates vigilant monitoring for this potential adverse event.
Gao et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: